<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68217</article-id><article-id pub-id-type="doi">10.7554/eLife.68217</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-230712"><name><surname>Castro-Mollo</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-187468"><name><surname>Gera</surname><given-names>Sakshi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1615-6259</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230728"><name><surname>Ruiz-Martinez</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230714"><name><surname>Feola</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230715"><name><surname>Gumerova</surname><given-names>Anisa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230729"><name><surname>Planoutene</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230730"><name><surname>Clementelli</surname><given-names>Cara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230731"><name><surname>Sangkhae</surname><given-names>Veena</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230732"><name><surname>Casu</surname><given-names>Carla</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230733"><name><surname>Kim</surname><given-names>Se-Min</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230734"><name><surname>Ostland</surname><given-names>Vaughn</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-230735"><name><surname>Han</surname><given-names>Huiling</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-230736"><name><surname>Nemeth</surname><given-names>Elizabeta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230737"><name><surname>Fleming</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230738"><name><surname>Rivella</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230739"><name><surname>Lizneva</surname><given-names>Daria</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214885"><name><surname>Yuen</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73636"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-115569"><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3496-3783</contrib-id><email>yelena.ginzburg@mssm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>The Mount Sinai Bone Program, Departments of Medicine and Pharmacological Sciences, and Center for Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Center for Iron Disorders, University of California, Los Angeles (UCLA)</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Pediatrics, Division of Hematology, and Penn Center for Musculoskeletal Disorders, Children’s Hospital of Philadelphia (CHOP), University of Pennsylvania, Perelman School of Medicine</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Intrinsic Lifesciences, LLC</institution><addr-line><named-content content-type="city">LaJolla</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Pediatrics, Saint Louis University School of Medicine</institution><addr-line><named-content content-type="city">St Louis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mohan</surname><given-names>Subburaman</given-names></name><role>Reviewing Editor</role><aff><institution>Loma Linda University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution>Medical College of Georgia at Augusta University</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>18</day><month>05</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68217</elocation-id><history><date date-type="received" iso-8601-date="2021-03-08"><day>08</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-17"><day>17</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Castro-Mollo et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Castro-Mollo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68217-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Erythroblast erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis.</p></sec><sec id="abs2"><title>Methods:</title><p>To address whether ERFE functions also in bone and whether the mechanism of ERFE action in bone involves BMPs, we utilize the <italic>Erfe<sup>-/-</sup></italic> mouse model as well as β–thalassemic (<italic>Hbb<sup>th3/+</sup></italic>) mice with systemic loss of ERFE expression. In additional, we employ comprehensive skeletal phenotyping analyses as well as functional assays in vitro to address mechanistically the function of ERFE in bone.</p></sec><sec id="abs3"><title>Results:</title><p>We report that ERFE expression in osteoblasts is higher compared with erythroblasts, is independent of erythropoietin, and functional in suppressing hepatocyte hepcidin expression. <italic>Erfe<sup>-/-</sup></italic> mice display low–bone–mass arising from increased bone resorption despite a concomitant increase in bone formation. Consistently, <italic>Erfe<sup>-/-</sup></italic> osteoblasts exhibit enhanced mineralization, <italic>Sost</italic> and <italic>Rankl</italic> expression, and BMP–mediated signaling ex vivo. The ERFE effect on osteoclasts is mediated through increased osteoblastic RANKL and sclerostin expression, increasing osteoclastogenesis in <italic>Erfe<sup>-/-</sup></italic> mice. Importantly, <italic>Erfe</italic> loss in <italic>Hbb<sup>th3/+</sup></italic>mice, a disease model with increased ERFE expression, triggers profound osteoclastic bone resorption and bone loss.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Together, ERFE exerts an osteoprotective effect by modulating BMP signaling in osteoblasts, decreasing RANKL production to limit osteoclastogenesis, and prevents excessive bone loss during expanded erythropoiesis in β–thalassemia.</p></sec><sec id="abs5"><title>Funding:</title><p>YZG acknowledges the support of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 DK107670 to YZG and DK095112 to RF, SR, and YZG). MZ acknowledges the support of the National Institute on Aging (U19 AG60917) and NIDDK (R01 DK113627). TY acknowledges the support of the National Institute on Aging (R01 AG71870). SR acknowledges the support of NIDDK (R01 DK090554) and Commonwealth Universal Research Enhancement (CURE) Program Pennsylvania.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>erythroferrone</kwd><kwd>thalassemia</kwd><kwd>bone formation</kwd><kwd>osteoporosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK107670</award-id><principal-award-recipient><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK095112</award-id><principal-award-recipient><name><surname>Fleming</surname><given-names>Robert</given-names></name><name><surname>Rivella</surname><given-names>Stefano</given-names></name><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK113627</award-id><principal-award-recipient><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG60917</award-id><principal-award-recipient><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK09055</award-id><principal-award-recipient><name><surname>Rivella</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG71870</award-id><principal-award-recipient><name><surname>Yuen</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK090554</award-id><principal-award-recipient><name><surname>Rivella</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The hepcidin regulator erythroferrone functions by sequestering BMPs and is an important modulator of bone remodeling, providing new mechanistic insight into how premature osteoporosis persists in optimally transfused β-thalassemic patients.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>It has become increasingly clear that both erythropoiesis and skeletal homeostasis are susceptible to changes in iron metabolism, especially during stress or ineffective erythropoiesis. Diseases of ineffective erythropoiesis, such as β-thalassemia, one of the most common forms of inherited anemia worldwide (<xref ref-type="bibr" rid="bib44">Weatherall et al., 2010</xref>), are thus associated with bone loss, primarily at cortical sites (<xref ref-type="bibr" rid="bib13">Haidar et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Vogiatzi et al., 2006</xref>). β-thalassemia results from β-globin gene mutations that cause ineffective erythropoiesis, splenomegaly, and anemia (<xref ref-type="bibr" rid="bib43">Weatherall, 1998</xref>; <xref ref-type="bibr" rid="bib29">Pootrakul et al., 1988</xref>; <xref ref-type="bibr" rid="bib31">Rund et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Centis et al., 2000</xref>). Patients with homozygous mutations have either red blood cell (RBC) transfusion-dependent β-thalassemia major (TDT) or a relatively milder anemia, namely non-transfusion-dependent β-thalassemia intermedia (NTDT).</p><p>Both TDT and NTDT generally present with anemia and iron overload, requiring iron chelation therapy. Surprisingly, however, TDT patients show more marked decrements in bone mineral density (BMD) compared with NTDT, despite chronic RBC transfusion that suppresses expanded and ineffective erythropoiesis. Optimization of RBC transfusion has reduced the frequency of overt bone disease, such as frontal bossing, maxillary hyperplasia, and limb deformities, and importantly, has enabled prolonged survival (<xref ref-type="bibr" rid="bib22">Kwiatkowski et al., 2012</xref>). Nonetheless, growth patterns have not significantly improved (<xref ref-type="bibr" rid="bib41">Wallace et al., 2009</xref>), and low bone mass remains a frequent, significant, and poorly understood complication even in optimally treated patients. As such, β-thalassemia-induced bone disease has warranted formal guidelines for management (<xref ref-type="bibr" rid="bib37">Thalassemia Clinical Research Network et al., 2015</xref>).</p><p>Proposed mechanisms of bone loss in β-thalassemia include direct effects of abnormal erythroid proliferation (<xref ref-type="bibr" rid="bib33">Schnitzler and Mesquita, 1998</xref>; <xref ref-type="bibr" rid="bib12">Gurevitch and Slavin, 2006</xref>), increased circulating erythropoietin (Epo) (<xref ref-type="bibr" rid="bib36">Singbrant et al., 2011</xref>), iron toxicity (<xref ref-type="bibr" rid="bib45">Weinberg, 2006</xref>), oxidative stress (<xref ref-type="bibr" rid="bib3">Basu et al., 2001</xref>), inflammation (<xref ref-type="bibr" rid="bib23">Lacativa and Farias, 2010</xref>), and changes in bone marrow adiposity (<xref ref-type="bibr" rid="bib34">Schwartz, 2015</xref>). Strong negative correlations between BMD and systemic iron concentrations (<xref ref-type="bibr" rid="bib15">Imel et al., 2016</xref>) and the profound bone loss noted in patients with hereditary hemochromatosis (<xref ref-type="bibr" rid="bib11">Guggenbuhl et al., 2006</xref>) underscore the premise that BMD and iron homeostasis may be associated causally. However, mice lacking the transferrin receptor, TFR2, display <italic>increased</italic> rather than decreased bone mass and mineralization despite iron overload (<xref ref-type="bibr" rid="bib30">Rauner et al., 2019</xref>). These latter findings prompted us to take a fresh look at the mechanisms underpinning bone loss in diseases of iron dysregulation.</p><p>Erythroferrone (ERFE), a protein secreted by bone marrow erythroblasts, is a potent negative regulator of hepcidin (<xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>); hepcidin inhibits iron absorption and recycling (<xref ref-type="bibr" rid="bib27">Nemeth et al., 2005</xref>). Thus, hepcidin suppression by increased ERFE enables an increase in iron availability during stress erythropoiesis. Very recently, ERFE has been shown to bind and sequester certain members of the bone morphogenetic protein (BMP) family, prominently BMP2, BMP6, and the BMP2/6 heterodimer (<xref ref-type="bibr" rid="bib1">Arezes et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Wang et al., 2020</xref>). BMPs stimulate bone formation by osteoblasts during skeletal development, modeling, and ongoing remodeling (<xref ref-type="bibr" rid="bib14">Hogan, 1996</xref>). We thus hypothesized that, by modifying BMP availability, ERFE may be a key player in the newly discovered erythropoiesis-iron-bone circuitry. As a result, ERFE may also be an important link between altered iron metabolism, abnormal erythropoiesis, and bone loss in β-thalassemia.</p><p>The known mechanism of ERFE action—BMP sequestration—predicts that ERFE loss, by enhancing BMP availability, may stimulate osteoblastic bone formation (<xref ref-type="bibr" rid="bib32">Salazar et al., 2016</xref>). Alternatively, recent literature shows that loss of BMP signaling increases bone mass through direct osteoclast inhibition and Wnt activation (<xref ref-type="bibr" rid="bib5">Broege et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Jensen et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Kamiya et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Kamiya et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Baud’huin et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Gooding et al., 2019</xref>), predicting that ERFE loss would lead to decreased bone mass. Here, we demonstrate that global deletion of <italic>Erfe</italic> in mice results in a low-bone-mass phenotype, which is phenocopied in β-thalassemic mice lacking ERFE (i.e. <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice). Despite the osteopenic phenotype, we found that ERFE loss stimulated mineralization in cell culture. The net loss of bone in <italic>Erfe<sup>-/-</sup></italic> mice in the face of a pro-osteoblastic action could therefore only be attributed to a parallel increase in bone resorption, which we found was the case in both <italic>Erfe<sup>-/-</sup></italic> and <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice. Furthermore, the increase in osteoclastogenesis was osteoblast-mediated exerted via an increased expression of <italic>Sost</italic> and <italic>Tnfsf11</italic>, the gene encoding RANKL. Together, our data provide compelling evidence that ERFE loss induces BMP-mediated osteoblast differentiation, but upregulates <italic>Sost</italic> and <italic>Tnfsf11</italic> to increase osteoclastogenesis with net bone loss. Therefore, high ERFE levels in β-thalassemia are osteoprotective and prevent the bone loss when erythropoiesis is expanded.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Mouse lines</title><p>C57BL/6 and β-thalassemic (<italic>Hbb<sup>th3/+</sup></italic>) mice (<xref ref-type="bibr" rid="bib46">Yang et al., 1995</xref>) were originally purchased from Jackson Laboratories. <italic>Erfe<sup>-/-</sup></italic> mice were a generous gift from Tomas Ganz (UCLA) (<xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>). Progeny of <italic>Erfe<sup>-/-</sup></italic>mice crossed with <italic>Hbb<sup>th3/+</sup></italic> yielded <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice. The mice have been backcrossed onto a C57BL/6 background for more than 11 generations. All mice had ad libitum access to food and water and were bred and housed in the animal facility under AAALAC guidelines. Experimental protocols were approved by the Institutional Animal Care and Use Committee at Icahn School of Medicine at Mount Sinai.</p></sec><sec id="s2-2"><title>Skeletal phenotyping</title><p>Skeletal phenotyping was conducted on 6-week- and/or 5-month-old male mice, unless otherwise noted. Mice were injected with calcein (15 mg/kg, Sigma C0875) and xylenol orange (90 mg/kg, Sigma 52097), at days 8 and 2, respectively, prior to sacrifice. Briefly, for histomorphometry, the left femur, both tibias, and L1-L3 were fixed in neutral buffered formalin (10%, v/v) for 48 hr at 4°C; transferred to sucrose (30%, w/v) at 4°C overnight; and embedded and sectioned at –25°C (5–6 µm thick sections, 10X) (<xref ref-type="bibr" rid="bib8">Dyment et al., 2016</xref>). Unstained sections were analyzed by fluorescence microscopy (Leica Upright DM5500) to determine the mineralizing surface and interlabel distance using image J. Von Kossa staining of sections was used to quantify fractional bone volume (BV/TV) and trabecular thickness (Tb.Th). Tartrate-resistant acid phosphatase (ACP5) staining (Sigma 387A) was used to identify osteoclasts, counterstained with aniline blue using Olympus Stereoscope MVX10 (1X). Images were analyzed by TrapHisto and OsteoidHisto (<xref ref-type="bibr" rid="bib38">van 't Hof et al., 2017</xref>). On the day of sacrifice, BMD was also measured in intact mice (<xref ref-type="bibr" rid="bib35">Shi et al., 2016</xref>). Frozen bone sections were incubated for 4 min at room temperature in Alkaline Phosphatase Substrate Solution ImmPACT Vector Red (Vector Laboratories). After washing with buffer, the sections were counterstained with hematoxylin (Vector Laboratories) and mounted with VectaMount AQ Mounting Medium (Vector Laboratories). Sections were visualized using Olympus BH-2 Microscope and images obtained with OMAX A35180U3 Camera were analyzed by ImageJ.</p></sec><sec id="s2-3"><title>Isolation and culture of bone marrow cells</title><p>For osteoblast cultures, fresh bone marrow cells were seeded in 12-well plates (0.6 × 10<sup>6</sup> cells <italic>per</italic> well) under differentiating conditions (αMEM, 10% FBS, 1% penicillin/streptomycin, 1 M β-glycerol phosphate, and 0.5 M ascorbic acid) for 21 days to induce the formation of mature, mineralizing osteoblast colonies, Cfu-ob, as before (<xref ref-type="bibr" rid="bib25">Maridas et al., 2018</xref>). Cultured osteoblasts were treated with BMP2 (50 ng/ml) or BMP6 (50 ng/ml) for 30 min on day 3 of culture to assess effects on BMP-mediated signaling, as previously (<xref ref-type="bibr" rid="bib30">Rauner et al., 2019</xref>). For osteoclast cultures, bone marrow hematopoietic stem cells (non–adherent) from wild type and <italic>Erfe<sup>-/-</sup></italic> were seeded in six-well plates (10<sup>6</sup> cells <italic>per</italic> well) in the presence of αMEM, 10% FBS, 1% penicillin/streptomycin and M-CSF (25 ng/mL, PeproTech) for 48 hr, followed by the addition of RANK-L (50 ng/mL, PeproTech) for 5 days. In experiments testing Epo responsiveness, 20 U/ml of Epo was added for the duration of the differentiation process, for 21 and 5 days in osteoblast and osteoclast cultures, respectively.</p><p>Erythroblasts were isolated from bone marrow and purified using CD45 beads, as previously (<xref ref-type="bibr" rid="bib24">Li et al., 2017</xref>) with minor modifications. Briefly, mouse femur was flushed, single-cell suspensions incubated with anti-CD45 magnetic beads (Mylteni), and erythroid lineage-enriched cells that flowed through the column were collected. Erythroid-enriched cells were incubated with anti-mouse TER119-phycoerythrin Cy7 (PE-Cy7) (BioLegend) and CD44-allophycocyanin (APC) (Tonbo, Biosciences). Non-erythroid and necrotic cells were identified and excluded from analyses using anti-CD45 (BD Pharmigen), anti-CD11b, and anti-Gr1 (APC-Cy7) (Tonbo, Biosciences) antibodies. Erythroid precursors were selected by gating and analyzed using TER119, CD44, and forward scatter as previously described (<xref ref-type="bibr" rid="bib24">Li et al., 2017</xref>). Samples were analyzed on either FACSCanto I or LSRFortessa flow cytometer (BD Biosciences). To determine levels of <italic>Erfe</italic> mRNA expression in Epo–stimulated conditions, erythroblasts were cultured in the presence or absence of 20 U/ml Epo for 15 hr as described (<xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>).</p></sec><sec id="s2-4"><title>Primary hepatocyte culture</title><p>Hepatocytes were isolated by perfusion with collagenase and liver digestion, as described previously (<xref ref-type="bibr" rid="bib26">Merlin et al., 2017</xref>). Briefly, 0.025% (w/v) collagenase type IV (Gibco) and 5 mM CaCl<sub>2</sub> was added to Leffert perfusion buffer containing 10 mM HEPES, 3 mM KCl, 130 mM NaCl, 1 mM NaH<sub>2</sub>PO<sub>4</sub>.H<sub>2</sub>O, and 10 mM D-glucose (Sigma). Live cells were purified by Percoll (Sigma) and plated in six-well plates (0.25 × 10<sup>6</sup> cells <italic>per</italic> well) in William’s Medium E (Sigma) supplemented with antibiotics and 5% fetal bovine serum (FBS) for 2 hr to allow the hepatocytes to attach. Cells were starved overnight with William’s Medium E lacking FBS, and were then treated for 6 hr with conditioned or control media from wild type or <italic>Erfe<sup>-/-</sup></italic> osteoblast and osteoclast cultures (day 6 and day 5, respectively) in the presence of 50% (v/v) William’s Medium E and 5% FBS.</p></sec><sec id="s2-5"><title>Quantitative PCR</title><p>RNA was purified from osteoblasts, osteoclasts, erythroblasts, and hepatocytes using PureLink RNA (Sigma) and analyzed with SuperScript III Platinum SYBR Green One-Step (Invitrogen). As previously described (<xref ref-type="bibr" rid="bib21">Koide et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Dumas et al., 2008</xref>), ΔΔCT values were used to calculate fold increases relative to β-actin, α-tubulin, and RLP4. Primers are listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Primers used in the presented studies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Gene</th><th valign="top">Forward (sense)</th><th valign="top">Reverse (antisense)</th></tr></thead><tbody><tr><td valign="top"><italic>Actb</italic></td><td valign="top"><named-content content-type="sequence">TTCTTTGCAGCTCCTTCGTT</named-content></td><td valign="top"><named-content content-type="sequence">ATGGAGGGGAATACAGCCC</named-content></td></tr><tr><td valign="top"><italic>Tubb</italic></td><td valign="top"><named-content content-type="sequence">CTGGAGCAGTTTGACGACAC</named-content></td><td valign="top"><named-content content-type="sequence">TGCCTTTGTGCACTGGTATG</named-content></td></tr><tr><td valign="top"><italic>Hamp</italic></td><td valign="top"><named-content content-type="sequence">TGAGCAGCACCACCTATCTC</named-content></td><td valign="top"><named-content content-type="sequence">ACTGGGAATTGTTACAGCATTT</named-content></td></tr><tr><td valign="top"><italic>Acp5</italic></td><td valign="top"><named-content content-type="sequence">ACCTGTGCTTCCTCCAGGAT</named-content></td><td valign="top"><named-content content-type="sequence">TCTCAGGGTGGGAGTGGG</named-content></td></tr><tr><td valign="top"><italic>Ctsk</italic></td><td valign="top"><named-content content-type="sequence">CCATATGTGGGCCAGGATG</named-content></td><td valign="top"><named-content content-type="sequence">TCAGGGCTTTCTCGTTCCC</named-content></td></tr><tr><td valign="top"><italic>Runx2</italic></td><td valign="top"><named-content content-type="sequence">GTGGCCACTTACCACAGAGC</named-content></td><td valign="top"><named-content content-type="sequence">GTTCTGAGGCGGGACACC</named-content></td></tr><tr><td valign="top"><italic>Alpl</italic></td><td valign="top"><named-content content-type="sequence">ACACCTTGACTGTGGTTACTGCTGA</named-content></td><td valign="top"><named-content content-type="sequence">CCTTGTAGCCAGGCCCGTTA</named-content></td></tr><tr><td valign="top"><italic>Osx</italic></td><td valign="top"><named-content content-type="sequence">TGAGGAAGAAGCCCATTCAC</named-content></td><td valign="top"><named-content content-type="sequence">GTGGTCGCTTCTGGTAAAGC</named-content></td></tr><tr><td valign="top"><italic>Col1a1</italic></td><td valign="top"><named-content content-type="sequence">CCTGGCAAAGACGGACTCAAC</named-content></td><td valign="top"><named-content content-type="sequence">GCTGAAGTCATAACCGCCACTG</named-content></td></tr><tr><td valign="top"><italic>Tnsf11</italic></td><td valign="top"><named-content content-type="sequence">CAGCCATTTGCACACCTCAC</named-content></td><td valign="top"><named-content content-type="sequence">GTCTGTAGGTACGCTTCCCG</named-content></td></tr><tr><td valign="top"><italic>Opg</italic></td><td valign="top"><named-content content-type="sequence">ACAGTTTGCCTGGGACCAAA</named-content></td><td valign="top"><named-content content-type="sequence">CAGGCTCTCCATCAAGGCAA</named-content></td></tr><tr><td valign="top"><italic>Dmp1</italic></td><td valign="top"><named-content content-type="sequence">GGGCTGTGTTGTGCAAGACA</named-content></td><td valign="top"><named-content content-type="sequence">GGTGCACACCTGACCTTCTTTAA</named-content></td></tr><tr><td valign="top"><italic>Fam132b</italic></td><td valign="top"><named-content content-type="sequence">ATGGGGCTGGAGAACAGC</named-content></td><td valign="top"><named-content content-type="sequence">TGGCATTGTCCAAGAAGACA</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s2-6"><title>Western immunoblotting and ELISA</title><p>For western immunoblotting, differentiated cells at day three were lysed in ice cold SDS page lysis buffer (2% SDS, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA) with protease and phosphatase inhibitors. 20 µg of heat–denatured protein was loaded onto a 10% gel, run, and transferred onto a 0.4 µm nitrocellulose membrane (Thermo Scientific). After blocking with 5% BSA in Tris–buffered saline with 1% Tween-20 (TBS-T), the membranes were incubated with primary antibodies to signaling proteins (<xref ref-type="table" rid="table2">Table 2</xref>) overnight at 4°C, washed, and incubated with the corresponding HRP–conjugated secondary antibodies at room temperature. Proteins were visualized using the ImageQuant LAS 4010 and quantified using Image J. Osteoblast supernatants from wild type and <italic>Erfe<sup>-/-</sup></italic> mice were collected and centrifuged for 10 min at 10,000 x g, and BMP2 (Abnova) and RANKL (R and D) concentrations were measured by ELISAs. Serum BMP2 concentration was determined using mouse BMP2 ELISA (abnova, KA0542), <italic>per</italic> manufacturers instructions. ERFE concentration in conditioned media was determined as described (<xref ref-type="bibr" rid="bib20">Kautz et al., 2015</xref>) with the substitution of DELFIA europium–conjugated streptavidin for horseradish-peroxidase-conjugated streptavidin. Fluorescence was measured by CLARIOstar plate reader.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Antibodies used in the presented studies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibody</th><th valign="top">Company</th><th valign="top"># catalog</th><th valign="top">Dilution</th><th valign="top">BSA/Milk (5%)</th><th valign="top">Rabbit/mouse</th></tr></thead><tbody><tr><td colspan="6" valign="top"><italic>PRIMARY antibodies</italic></td></tr><tr><td valign="top">pSMAD 1/5/8</td><td valign="top">Cell signaling</td><td valign="top">9511</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">pSMAD 1/5/8 (monoclonal)</td><td valign="top">Cell signaling</td><td valign="top">9516</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">SMAD 1</td><td valign="top">Cell signaling</td><td valign="top">6944S</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">p-ERK <break/>(monoclonal)</td><td valign="top">Cell signaling</td><td valign="top">4376</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">ERK</td><td valign="top">Cell signaling</td><td valign="top">4695</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">pp38</td><td valign="top">Cell signaling</td><td valign="top">4511</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">p38</td><td valign="top">Cell signaling</td><td valign="top">8690</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Rabbit</td></tr><tr><td valign="top">Beta-actin</td><td valign="top">ThermoFisher</td><td valign="top">MA515452</td><td valign="top">1:1000</td><td valign="top">BSA</td><td valign="top">Mouse</td></tr><tr><td colspan="6" valign="top"><italic>SECONDARY antibodies</italic></td></tr><tr><td valign="top">Rabbit</td><td valign="top">Cell signaling</td><td valign="top">7074</td><td valign="top">1:5000</td><td valign="top">BSA</td><td valign="top"/></tr><tr><td valign="top">Mouse</td><td valign="top">GE Healthcare</td><td valign="top">NXA931V</td><td valign="top">1:20000</td><td valign="top">BSA</td><td valign="top"/></tr></tbody></table></table-wrap></sec><sec id="s2-7"><title>Complete blood counts</title><p>Peripheral blood (100 µL from each mouse) was collected from the retro-orbital vein in EDTA-coated tubes and analyzed by IDEXX Procyte Hematology Analyzer.</p></sec><sec id="s2-8"><title>Statistical analyses</title><p>Data are reported as means ± SEM. Unpaired Student’s t-test was used to determine if differences between groups were significant at p&lt;0.05.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>To understand if ERFE has a role in regulating skeletal integrity in health, we first studied the effect of ERFE loss on BMD and bone remodeling in adult <italic>Erfe<sup>-/-</sup></italic> mice, as well as in compound mutant mice in which the <italic>Erfe</italic> gene was deleted on a β-thalassemia <italic>Hbb<sup>th3/+</sup></italic> background. Compared with wild-type littermates, both 6-week-old and 5-month-old male <italic>Erfe<sup>-/-</sup></italic> mice showed significant reductions in whole body BMD, and BMD at mainly cortical (femur and tibia) sites (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). However, in contrast to young mice, the older <italic>Erfe<sup>-/-</sup></italic> mice did not show a difference in lumbar spine BMD compared with wild-type littermates. Interestingly, unlike hypogonadal bone loss, which is predominantly trabecular, the sustained reduction in femur and tibia BMD is consistent with prominent cortical loss seen in patients with β-thalassemia (<xref ref-type="bibr" rid="bib13">Haidar et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Vogiatzi et al., 2006</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>ERFE loss results in high turnover osteoporosis.</title><p>Bone mineral density (BMD) measured in whole body, femur, tibia, and lumbar spine (<bold>L4–L6</bold>) along with bone volume (BV/TV) and trabecular thickness (Tb.Th) in growing (6-week-old) (<bold>A</bold>) and mature (5-month-old) (<bold>B</bold>) <italic>Erfe</italic><sup>-/-</sup> and wild-type (WT) littermates. Dynamic histomorphometry following two i.p. injections of calcein (green) and xylenol orange (red) given at days 8 and 2, respectively. Representative dual labels from the epiphysis are shown, together with measured and derived parameters, namely mineralizing surface (MS) as a function of bone surface (BS), mineral apposition rate (MAR) and bone formation rate (BFR) in 6-week-old (<bold>C</bold>) and 5-month-old (<bold>D</bold>) mice. (<bold>E</bold>) Alkaline phosphatase staining (magenta) in sections of femura demonstrates no differences in osteoblast surface (Ob.S) and number (N.Ob) as a function of BS in 6-week-old <italic>Erfe</italic><sup>-/-</sup> and WT mice. (<bold>F</bold>) TRAP staining at the epiphysis showing both osteoclast surface (Oc.S) and number (N.Oc) as a function of BS. Statistics: Mean ± SEM; unpaired two-tailed Student’s t-test; *p&lt;0.05, **p&lt;0.01, ^0.05 &lt; p &lt; 0.1, <italic>N</italic> = 3–6 mice per group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Erythropoiesis-related parameters in Erfe-/- mice.</title><p>We confirm previously reported lack of difference relative to wild-type (WT) mice in red blood cell (RBC) count (<bold>A</bold>), hemoglobin (<bold>B</bold>), mean corpuscular hemoglobin (MCH) (<bold>C</bold>), reticulocyte count (<bold>D</bold>), spleen weight (<bold>E</bold>), and bone marrow erythroblast fraction (<bold>F</bold>). Statistics: Mean ± SEM; unpaired two-tailed Student's <italic>t</italic>-test; N = 4–5 mice per group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Bone resorption and bone formation are tightly coupled to maintain bone mass during each remodeling cycle (<xref ref-type="bibr" rid="bib48">Zaidi, 2007</xref>). Bone is lost when either both processes are increased―with resorption exceeding formation, as in hypogonadism―or when there is uncoupling in which formation decreases while resorption rises, as in glucocorticoid excess (<xref ref-type="bibr" rid="bib48">Zaidi, 2007</xref>). To differentiate between relative increases and uncoupling, we measured both formation and resorption in intact bone. Dynamic histomorphometry performed after the sequential injections of calcein and xylenol orange, which yielded dual fluorescent labels, allowed us to derive parameters of bone formation. We observed that mineralizing surface (MS), mineral apposition rate (MAR) and bone formation rates (BFR) were all increased in young <italic>Erfe<sup>-/-</sup></italic> mice, consistent with the pro-osteoblastic (anabolic) action of ERFE deficiency (see below) (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). No differences in MS, MAR, and BFR were noted in 5-month-old mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We also analyzed alkaline phosphatase stained sections of femurs to find no difference in osteoblast surfaces (Ob.S) or osteoblast number (N.Ob) <italic>per</italic> bone surface (BS) in 5–week–old <italic>Erfe<sup>-/-</sup></italic> relative to wild type littermates (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>Finally, to study whether an increase in osteoclastic bone resorption caused the notable reduction in BMD in <italic>Erfe<sup>-/-</sup></italic> mice, we measured TRAP-positive osteoclast surfaces (Oc.S) and number (N.Oc) <italic>per</italic> bone surface (BS). Both Oc.S/BS and N.Oc/BS were increased significantly in <italic>Erfe<sup>-/-</sup></italic> compared with wild type bones in older mice, and to a lesser extent, in younger mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Thus, the overall low-bone-mass phenotype in <italic>Erfe<sup>-/-</sup></italic> mice primarily resulted from a relative increase in osteoclastic bone resorption over osteoblastic bone formation, suggesting that ERFE has a function in preventing skeletal loss. To confirm that decreased BMD in <italic>Erfe<sup>-/-</sup></italic> mice did not result from changes in erythropoiesis, we measured circulating red blood cells (RBCs) and reticulocytes, and bone marrow erythroblasts. We also measured spleen weight given the ubiquity of compensatory erythropoiesis that results in splenomegaly. Our results show no differences between 6-week-old wild type and <italic>Erfe<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), consistent with what has been previously reported in <italic>Erfe<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>).</p><p>To probe the mechanism of action of ERFE on osteoblastic bone formation and osteoclastic bone resorption, we first asked which cells in bone marrow produce ERFE, and whether secreted ERFE was functional. Intriguingly, time course studies in differentiating osteoblasts revealed that <italic>Erfe</italic> expression was 10- and twofold higher at 3 and 21 days of culture, respectively, compared with cultured erythroblasts––the only previously known source of ERFE in bone marrow (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To confirm that cultured cells were of the osteoblastic lineage, we evaluated <italic>Alp</italic> expression, a known marker of osteoblast lineage, and demonstrate increased <italic>Alp</italic> expression as early as day 3 in culture (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Furthermore, <italic>Erfe</italic> expression in mature osteoclasts was similar to cultured erythroblasts, with little expression in immature osteoclasts (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Likewise, conditioned media from osteoblast cultures revealed increased ERFE concentration at 3 days with no differences in conditioned media from osteoclast cultures (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>ERFE is expressed at higher levels in osteoblasts than in erythroblasts.</title><p>(<bold>A</bold>) Quantitative PCR showing high levels of <italic>Erfe</italic> expression in osteoblasts from wild type mice cultured under differentiating conditions. Notably, at 3 days of culture, there was a 10-fold greater expression in osteoblasts relative to bone-marrow-derived wild-type cultured erythroblasts. (<bold>B</bold>) Quantitative PCR showing comparable levels of <italic>Erfe</italic> expression in osteoclasts at 3–5 days of culture relative to bone-marrow-derived wild-type cultured erythroblasts from wild-type mice cultured under differentiating conditions. (<bold>C</bold>) Increased supernatant murine ERFE (mERFE) concentration in day 3 osteoblast cultures and no difference in day 5 osteoclast cultures from wild type relative to <italic>Erfe</italic><sup>-/-</sup> mice (detection limit of 0.2 ng/ml mERFE). (<bold>D</bold>) Hepcidin (HAMP) expression is suppressed in primary wild-type hepatocytes in response to conditioned media from wild-type relative to <italic>Erfe</italic><sup>-/-</sup> osteoblast cultures (day 6), confirming functionality of osteoblast-derived ERFE. Control hepatocytes were exposed to osteoblast culture media. (<bold>E</bold>) Unlike in erythroblasts, <italic>Erfe</italic> expression in cultured wild-type osteoblasts and osteoclasts does not respond to erythropoietin (Epo). Statistics: Mean ± SEM; unpaired two-tailed Student’s t-test; *p&lt;0.05, **p&lt;0.01, ^0.05 &lt; <italic>P</italic> &lt; 0.1, <italic>N</italic> = 3 wells per group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Alkaline phosphatase expression increased during osteoblast differentiation in culture.</title><p>As expected, alkaline phosphatase is increased in ostoblast culture conditions at day 3 and day 6, providing evidence of osteoblasts at the expected time frame. Statistics: Mean ± SEM; unpaired two-tailed Student's <italic>t</italic>-test; *p&lt;0.05, **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To determine whether osteoblast-derived ERFE was functional, we established a bioassay based on the known inhibitory action of ERFE on hepcidin (<italic>Hamp</italic>) expression. For this, wild-type hepatocytes were exposed to supernatants from differentiating wild type or <italic>Erfe<sup>-/-</sup></italic> osteoblasts. <italic>Hamp</italic> expression was suppressed with <italic>Erfe<sup>-/-</sup></italic> osteoblast supernatants, but importantly, this suppression was significantly greater with wild type supernatants (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). No <italic>Hamp</italic> suppression was evident with wild type or <italic>Erfe<sup>-/-</sup></italic> osteoclast supernatants. This latter suggests that osteoblast– but not osteoclast-derived ERFE is functional. However, as <italic>Erfe<sup>-/-</sup></italic> supernatants also suppressed <italic>Hamp</italic> expression, other yet unknown osteoblast-derived factors likely function in hepcidin regulation. Finally, unlike in erythroblasts, <italic>Erfe</italic> expression in mature osteoblasts or osteoclasts was not responsive to Epo (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>Given that osteoblasts secrete ERFE that is known to inhibit hepcidin (<xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>) by sequestering BMPs (<xref ref-type="bibr" rid="bib1">Arezes et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Arezes et al., 2020</xref>) that are skeletal anabolics (<xref ref-type="bibr" rid="bib14">Hogan, 1996</xref>), we measured serum BMP2 concentration to find elevated BMP2 levels in <italic>Erfe<sup>-/-</sup></italic> relative to wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Given the specific importance of BMP2 in bone remodeling (<xref ref-type="bibr" rid="bib32">Salazar et al., 2016</xref>), these results are consistent with the previously demonstrated sequestration of BMP2, along with BMP6, by ERFE (<xref ref-type="bibr" rid="bib42">Wang et al., 2020</xref>)—namely, loss of ERFE led to decreased BMP sequestration. We thus hypothesized that ERFE functions in modulating bone formation by sequestering BMPs and tested whether the loss of ERFE facilitates BMP2-mediated signaling in the osteoblast in vitro. We found that the concentration of BMP2 was higher in supernatants from cultured <italic>Erfe<sup>-/-</sup></italic> osteoblasts compared with wild type cultures (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Consistent with this difference, BMP2-activated signaling pathways, namely phosphorylated Smad1/5/8 and ERK1/2, but not phosphorylated p38, were enhanced in <italic>Erfe<sup>-/-</sup></italic> compared with wild-type osteoblasts (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>ERFE function on bone involves BMP-2 sequestration.</title><p>(<bold>A</bold>) BMP2 ELISA demonstrates elevated BMP2 concentration in serum samples from <italic>Erfe</italic><sup>-/-</sup> relative to WT mice (<italic>N</italic> = 4 per group). In the 3-day cultures, there was an increase in BMP2 concentration in culture supernatants from <italic>Erfe</italic><sup>-/-</sup> relative to WT osteoblasts (<italic>N</italic> = 6 per group) (<bold>B</bold>). (<bold>C</bold>) Similarly, signaling via the known BMP receptor pathways, namely ERK1/2 and Smad1/5/8, without changes in p38/MAPK, increase in <italic>Erfe</italic><sup>-/-</sup> relative to WT osteoblasts; western blots with quantification shown. Finally, pSmad1/5/8 and pERK1/2 signaling is further induced by BMP2 (50 ng/ml) only in WT (<bold>D</bold>) but not in <italic>Erfe</italic><sup>-/-</sup> (<bold>E</bold>) osteoblasts. Statistics: Mean ± SEM; unpaired two-tailed Student’s t-test; *p&lt;0.05, **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>ERFE function on bone involves BMP-6 sequestration.</title><p>Similarly to effects of BMP2, signaling via the known BMP receptor pathways, namely ERK1/2 and Smad1/5/8, was further induced by BMP6 (50 ng/ml) only in WT but not in <italic>Erfe<sup>-/-</sup></italic> osteoblasts. Statistics: Mean ± SEM; unpaired two-tailed Student's <italic>t</italic>-test; ^0.05 &lt; p &lt; 0.1, **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To further understand how ERFE impacts BMP2-mediated signaling, we evaluated the effect of BMP2 on wild type and <italic>Erfe<sup>-/-</sup></italic> osteoblasts in vitro. Treatment with BMP2 (50 ng/ml) in osteoblast cultures showed that pSmad1/5/8 and pERK signaling was not further induced in <italic>Erfe<sup>-/-</sup></italic> relative to wild-type osteoblasts (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). In all, the data establish that increased BMP2 in <italic>Erfe<sup>-/-</sup></italic> mice leads to maximal induction of BMP signaling that remains unaffected by the further addition of BMP2. To test whether an ERFE effect on bone is BMP2 specific, we also repeated these experiments using BMP6, demonstrating results similar to the effects of BMP2 on BMP signaling pathways in wild type and <italic>Erfe<sup>-/-</sup></italic> osteoblasts in vitro (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). These findings support the hypothesis that ERFE functions in bone by sequestering BMPs, thus, attenuating downstream signaling.</p><p>We studied whether the stimulation of bone formation in <italic>Erfe<sup>-/-</sup></italic> mice was due to a cell–autonomous action of ERFE on osteoblasts. For this, we compared the ability of wild type and <italic>Erfe<sup>-/-</sup></italic> bone marrow stromal cells ex vivo to differentiate into mature mineralizing colony forming units–osteoblastoid (Cfu-ob). Stromal cells from 5-month-old <italic>Erfe<sup>-/-</sup></italic> mice showed enhanced von Kossa staining of mineralizing Cfu-ob colonies (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This mineralizing phenotype was associated with enhanced expression of the osteoblast transcription factors <italic>Runx2</italic> and <italic>Sp7</italic>, and downstream genes <italic>Sost</italic> and <italic>Tnfsf11</italic> (<xref ref-type="bibr" rid="bib47">Yang et al., 2010</xref>; <xref ref-type="bibr" rid="bib28">Pérez-Campo et al., 2016</xref>), increased supernatant RANKL levels, and suppressed expression of <italic>Opg</italic> (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Enhanced RANKL profoundly increases osteoclastogenesis, as noted below, while sclerostin, encoded by the <italic>Sost</italic> gene, reduces the production of OPG, hence further increasing osteoclast formation.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mechanism of action of ERFE on bone involves interplay between osteoblastic RANKL and sclerostin.</title><p>Osteoblasts from 5-month-old wild type and <italic>Erfe</italic><sup>-/-</sup> mouse bone marrow cultured under differentiating conditions for 5 or 21 days. Loss of ERFE resulted in accelerated mineralization, noted by an increase in Von Kossa-stained nodules (<bold>A</bold>). Consistent with the cellular phenotype is the upregulation in <italic>Erfe</italic><sup>-/-</sup> osteoblasts of <italic>Runx2</italic>, <italic>Sp7</italic>, <italic>Sost</italic>, and <italic>Tnfsf11</italic> expression and suppression of <italic>Opg</italic> expression (quantitative PCR on 21-day cultures) (<bold>B</bold>) as well as increased secreted RANKL (ELISA on 3 day cultures) (<bold>C</bold>). In vitro osteoclastogenesis assays show that ERFE loss does not alter osteoclast number, as measured by TRAP staining (<bold>D</bold>), or the expression of osteoclast genes, namely <italic>Acp5</italic> or <italic>Ctsk</italic> (<bold>E</bold>). Statistics: Mean ± SEM; unpaired two-tailed Student’s t-test; *p&lt;0.05, **p&lt;0.01; wells per group – three for A-C.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig4-v2.tif"/></fig><p>Given that <italic>Erfe</italic> is expressed in osteoclasts, and that <italic>Erfe<sup>-/-</sup></italic> mice display a pro–resorptive phenotype, we questioned whether ERFE directly affected the osteoclast, or whether the action resulted via a primary osteoblastic effect. <italic>Erfe<sup>-/-</sup></italic> bone marrow cell cultures derived from 5-month-old mice showed no difference in TRAP-positive osteoclast number compared to wild-type cultures (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Consistent with this, the program of osteoclast gene expression remained unchanged in these 5-day cultures (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The data collectively suggest that the absence of ERFE results in the de-sequestration of BMP2, stimulates the osteoblast to upregulate RANKL and sclerostin, and thus enhances osteoclastic bone resorption indirectly.</p><p>Finally, we explored whether ERFE mediates osteoprotection in <italic>Hbb<sup>th3/+</sup></italic> mice, a model of human NTDT given that <italic>Erfe</italic> is upregulated in <italic>Hbb<sup>th3/+</sup></italic> marrow erythroblasts (<xref ref-type="bibr" rid="bib39">Vogiatzi et al., 2006</xref>; <xref ref-type="bibr" rid="bib19">Kautz et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Kautz et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Vogiatzi et al., 2010</xref>). We crossed <italic>Hbb<sup>th3/+</sup></italic> mice with <italic>Erfe<sup>-/-</sup></italic> mice to generate <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> compound mutants. Whole body and site-specific measurements at mainly cortical sites, namely femur and tibia, and vertebral trabecular (L4-L6) bone showed striking reductions in BMD in 5-month-old <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mutants compared with <italic>Hbb<sup>th3/wt</sup></italic> mice, most notably in cortical bone (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The trabecular bone loss was consistent with reduced histomorphometrically determined fractional bone volume (BV/TV) and trabecular thickness (Tb.Th) in the femoral epiphyses (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). There was a trend toward increases in MAR (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), but a significant increase in TRAP-positive N.Oc and Oc.S in <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> bones compared with wild-type controls (<xref ref-type="fig" rid="fig5">Figure 5D</xref>)—changes expected to produce reduction in bone mass. These findings document ERFE-mediated skeletal protection in β-thalassemia.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>ERFE loss in β-thalassemia mice causes profound bone loss.</title><p>(<bold>A</bold>) Bone mineral density (BMD) measured in whole body, femur, tibia, and lumbar spine (<bold>L4–L6</bold>) in 5-month-old β-thalassemia mice (<italic>Hbb</italic><sup>th3/+</sup> mice) and compound <italic>Hbb</italic><sup>th3/+</sup>;<italic>Erfe</italic><sup>-/-</sup> mutants. (<bold>B</bold>) Representative section of femoral epiphyses stained with Von Kossa, and quantitative estimates of bone volume (BV/TV) and trabecular thickness (Tb.Th). (<bold>C</bold>) Dynamic histomorphometry following two i.p. injections of calcein (green) and xylenol orange (red) given at days 8 and 2, respectively. Shown are measured and derived parameters, namely mineralizing surface (MS), mineral apposition rate (MAR) and bone formation rate (BFR). (<bold>D</bold>) Representative image of TRAP (ACP5) staining of femoral epiphysis, also showing both osteoclast surface (Oc.S) and number (N.Oc), expressed as a function of bone surface (BS). Statistics: Mean ± SEM; unpaired two-tailed Student’s t-test; *p&lt;0.05, **p&lt;0.01; <italic>N</italic> = 4–5 mice per group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Erythropoiesis-related parameters in Hbb<sup>th3/+</sup> and Hbb<sup>th3/+;</sup><italic>Erfe</italic><sup>-/-</sup>mutant mice.</title><p>We confirm previously reported differences in relative to wild-type (WT) mice with decreased red blood cell (RBC) count (<bold>A</bold>), hemoglobin (<bold>B</bold>), and mean corpuscular hemoglobin (MCH) (<bold>C</bold>) as well as increased reticulocyte count (<bold>D</bold>), spleen weight (<bold>E</bold>), and bone marrow erythroblast fraction (<bold>F</bold>) with only minor differences in RBC count and hemoglobin between Hbb<sup>th3/+</sup> and compound Hbb<sup>th3/+;</sup>Erfe<sup>-/-</sup> mutant mice. Statistics: Mean ± SEM; unpaired two-tailed Student's <italic>t</italic>test; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.0001; N = 4–5 mice per group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To confirm that decreased BMD in <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice did not result from further expanded erythropoiesis, we measured circulating RBCs and reticulocytes, bone marrow erythroblasts, and spleen weight. Our results demonstrate a mildly decreased RBC count and hemoglobin, but no differences in spleen weight or bone marrow erythroblasts between 6-week-old <italic>Hbb<sup>th3/+</sup></italic> and <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). This is consistent with what has been previously reported in <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib20">Kautz et al., 2015</xref>).</p></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>To date, the only known function of ERFE was on hepatocellular hepcidin expression exerted through the sequestration of BMPs (<xref ref-type="bibr" rid="bib1">Arezes et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Wang et al., 2020</xref>). Using genetically–modified mice and in vitro assays, we identify a new role for ERFE in skeletal protection. First, we show that <italic>Erfe</italic> expression is higher in osteoblasts comapred with erthyroblasts. Second, we find that ERFE is a potent down-regulator of BMP2–mediated signaling and RANK-L production by osteoblasts. Third, ERFE loss in vivo enhances bone formation, while also stimulating resorption by inducing the expression of osteoblastic <italic>Tnfsf11</italic> and <italic>Sost.</italic> The net effect of these opposing changes is bone loss in both young and old mice (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Fourth, although also produced by osteoclasts, ERFE displays no cell-autonomous actions on osteoclast function. Taken together, and consistent with prior inferences (<xref ref-type="bibr" rid="bib5">Broege et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Jensen et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Kamiya et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Kamiya et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Baud’huin et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Gooding et al., 2019</xref>), ERFE functions to protect the skeleton by negatively regulating BMP signaling in osteoblasts, with indirect inhibitory effects on osteoclastic bone resorption.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Putative osteoprotective function of ERFE in health and in β-thalassemia.</title><p>In conditions of elevated ERFE (<bold>A</bold>), sich as β-thalassemia, more BMP2 and BMP6 is sequestered, decreasing signaling through the BMP/Smad and ERK pathways. This would result in decreased <italic>Sost</italic> and <italic>Rankl</italic> expression to decrease osteoclastogenesis and bone resorption. In contrast, when ERFE is low (<bold>B</bold>), increased BMP2, and possibly BMP6, leads to increased osteoclastogenesis with consequent decrease in bone formation. (<bold>C</bold>) Together, ERFE loss leads to a greater degree of progressively increased bone resorption relative to bone formation with age. ERFE = erythroferrone; BMP = bone morphogenetic protein; BMPR = BMP receptor; SOST = Sclerostin; RANKL = receptor activator of nuclear factor kappa-B ligand; OPG = osteoprotegrin; LRP = lipoprotein receptor-related protein; Wnt = wingless type MMTV integration site family.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-fig6-v2.tif"/></fig><p>Bone is a highly dynamic and purposefully organized tissue which undergoes constant remodeling in response to changing metabolic and mechanical needs. Bone remodeling is a process in which bone resorption by osteoclasts is balanced by synthesis of new bone by osteoblasts, which then undergo terminal differentiation to become mechanosensory osteocytes. Multiple local cytokines and systemic hormones regulate the delicate balance of bone resorption and bone formation, enabling bone cells to communicate among themselves as well as with other cells in the bone marrow. For example, osteocytes secrete Sclerostin, encoded by the SOST gene, which, in turn, inhibits further osteoblast differentiation. Osteoblasts and osteocytes also secrete RANKL and OPG. Osteoclasts express RANK, the RANKL receptor, and binding stimulates the differentiation of osteoclast precursors into mature osteoclasts; OPG sequesters RANKL to prevent unrestricted osteoclast differentiation. SOST optimizes the relative proportion of RANKL and OPG to induce bone resorption. Our findings demonstrate that while ERFE loss leads to increased bone mineralization in vitro and bone formation increases as expected with age, the composite effect in vivo results in greater enhancement of osteoclastogenesis relative to osteoblastogenesis in <italic>Erfe</italic><sup>-/-</sup> relative to wild-type mice, consequently decreasing BMD (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>We intentionally compared growing (6-week-old) and mature (5-month-old) mice to assess the potentially distinct or cumulative effect of ERFE loss on bone growth and/or remodeling, respectively. Our results demonstrate that ERFE loss leads to impaired BMD in both cohorts of mice. However, while MS/BS, MAR, BFR, and BV/TV are increased in 6-week-old <italic>Erfe</italic><sup>-/-</sup> relative to wild-type mice, no differences are evident between 5-month-old <italic>Erfe</italic><sup>-/-</sup> and wild-type mice. These findings strongly suggest that over time, while both bone formation and resorption increase relative to younger mice, the balance between them favors bone resorption (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). This interpretation is further corroborated by a more profound increase in osteoclast surface and osteoclast number in 5-month-old <italic>Erfe</italic><sup>-/-</sup> relative to wild type than in 6-week-old mice.</p><p>We show that supernatants from wild-type osteoblast cultures suppress <italic>Hamp</italic> expression, suggesting that BMP sequestration is likely a common mechanism that underpins both the hepatocellular and skeletal actions of ERFE. Recombinant ERFE binds certain bone-active BMPs, namely BMP2, BMP6, and the BMP2/6 heterodimer (<xref ref-type="bibr" rid="bib1">Arezes et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Wang et al., 2020</xref>), of which BMP2 is most relevant to adult bone formation (<xref ref-type="bibr" rid="bib32">Salazar et al., 2016</xref>). We posit that ERFE is a negative regulator of osteoblastic bone formation, and that the absence of ERFE increases bioavailable BMP to promote osteoblast differentiation. Our results indeed demonstrate that BMP2 levels are elevated in supernatants from cultured <italic>Erfe<sup>-/-</sup></italic> osteoblasts, with enhanced downstream signals, notably phosphorylated Smad1/5/8 and ERK1/2. In all, the findings provide strong support for BMP sequestration as the mechanism of action of ERFE on bone.</p><p>We have also used the β-thalassemia mouse, <italic>Hbb<sup>th3/+</sup></italic>, as a relevant disease model to study a role for ERFE in β-thalassemia, a condition with known elevations in ERFE. The results presented reflect evidence derived from analysis of male mice. We anticipate that similar differences would be expected in female mice. Chronic erythroid expansion in β-thalassemia is associated with a thinning of cortical bone resulting in bone loss (<xref ref-type="bibr" rid="bib13">Haidar et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Vogiatzi et al., 2006</xref>). It is therefore surprising that patients with the more severe forms of β-thalassemia, namely TDT, in whom RBC transfusions lead to suppression of endogenous erythropoiesis, exhibit significantly greater decrements in BMD than NTDT patients (<xref ref-type="bibr" rid="bib40">Vogiatzi et al., 2010</xref>). We have previously shown that ERFE is suppressed post-transfusion in TDT patients, and is significantly higher in NTDT patients (<xref ref-type="bibr" rid="bib9">Ganz et al., 2017</xref>). Our finding of a marked reduction of bone mass in <italic>Hbb<sup>th3/+</sup></italic> mice with genetically deleted <italic>Erfe</italic> (or <italic>Hbb<sup>th3/+</sup>;Erfe<sup>-/-</sup></italic> mice) compared with <italic>Hbb<sup>th3/+</sup></italic> mice provides strong evidence for a protective function of ERFE in preventing further worsening of the bone loss phenotype in β-thalassemia.</p><p>Taken together, our findings uncover ERFE as a novel regulator of bone mass via its modulation of BMP signaling in osteoblasts. In addition, because RBC transfusion suppresses erythropoiesis and thus decreases ERFE in both mice (<xref ref-type="bibr" rid="bib20">Kautz et al., 2015</xref>) and patients (<xref ref-type="bibr" rid="bib9">Ganz et al., 2017</xref>) with β-thalassemia, a relative decrement of ERFE may explain the more severe bone disease in TDT than in NTDT patients. As a consequence, our findings identify ERFE as a promising new therapeutic target for hematologic diseases associated with bone loss, such as β-thalassemia.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We sincerely appreciate Tomas Ganz and Chun-Ling (‘Grace’) Jung (UCLA), as well as Martina Rauner (University of Dresden) for many stimulating and helpful discussions and Ronald Hoffman (Icahn School of Medicine at Mount Sinai) for continued mentoring and advocacy. YZG acknowledges the support of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 DK107670 to YZG and DK095112 to RF, SR, and YZG). MZ acknowledges the support of the National Institute on Aging (U19 AG60917) and NIDDK (R01 DK113627). TY acknowledges the support of the National Institute on Aging (R01 AG71870). SR acknowledges the support of NIDDK (R01 DK090554) and Commonwealth Universal Research Enhancement (CURE) Program Pennsylvania.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf4"><p>Deputy editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is affiliated with Intrinsic Lifesciences, LLC. The author has no other competing interests to declare.</p></fn><fn fn-type="COI-statement" id="conf3"><p>is affiliated with Intrinsic Lifesciences, LLC. The author has no other competing interests to declare.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Validation, Investigation, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#16-0143) of the Icahn School of Medicine.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Source data file for presented studies.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68217-data1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-68217-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arezes</surname> <given-names>J</given-names></name><name><surname>Foy</surname> <given-names>N</given-names></name><name><surname>McHugh</surname> <given-names>K</given-names></name><name><surname>Sawant</surname> <given-names>A</given-names></name><name><surname>Quinkert</surname> <given-names>D</given-names></name><name><surname>Terraube</surname> <given-names>V</given-names></name><name><surname>Brinth</surname> <given-names>A</given-names></name><name><surname>Tam</surname> <given-names>M</given-names></name><name><surname>LaVallie</surname> <given-names>ER</given-names></name><name><surname>Taylor</surname> <given-names>S</given-names></name><name><surname>Armitage</surname> <given-names>AE</given-names></name><name><surname>Pasricha</surname> <given-names>S-R</given-names></name><name><surname>Cunningham</surname> <given-names>O</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Draper</surname> <given-names>SJ</given-names></name><name><surname>Jasuja</surname> <given-names>R</given-names></name><name><surname>Drakesmith</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Erythroferrone inhibits the induction of hepcidin by BMP6</article-title><source>Blood</source><volume>132</volume><fpage>1473</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-06-857995</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arezes</surname> <given-names>J</given-names></name><name><surname>Foy</surname> <given-names>N</given-names></name><name><surname>McHugh</surname> <given-names>K</given-names></name><name><surname>Quinkert</surname> <given-names>D</given-names></name><name><surname>Benard</surname> <given-names>S</given-names></name><name><surname>Sawant</surname> <given-names>A</given-names></name><name><surname>Frost</surname> <given-names>JN</given-names></name><name><surname>Armitage</surname> <given-names>AE</given-names></name><name><surname>Pasricha</surname> <given-names>S-R</given-names></name><name><surname>Lim</surname> <given-names>PJ</given-names></name><name><surname>Tam</surname> <given-names>MS</given-names></name><name><surname>Lavallie</surname> <given-names>E</given-names></name><name><surname>Pittman</surname> <given-names>DD</given-names></name><name><surname>Cunningham</surname> <given-names>O</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>JE</given-names></name><name><surname>Draper</surname> <given-names>SJ</given-names></name><name><surname>Jasuja</surname> <given-names>R</given-names></name><name><surname>Drakesmith</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia</article-title><source>Blood</source><volume>135</volume><fpage>547</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003140</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Michaëlsson</surname> <given-names>K</given-names></name><name><surname>Olofsson</surname> <given-names>H</given-names></name><name><surname>Johansson</surname> <given-names>S</given-names></name><name><surname>Melhus</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Association between Oxidative Stress and Bone Mineral Density</article-title><source>Biochemical and Biophysical Research Communications</source><volume>288</volume><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5747</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baud’huin</surname> <given-names>M</given-names></name><name><surname>Solban</surname> <given-names>N</given-names></name><name><surname>Cornwall-Brady</surname> <given-names>M</given-names></name><name><surname>Sako</surname> <given-names>D</given-names></name><name><surname>Kawamoto</surname> <given-names>Y</given-names></name><name><surname>Liharska</surname> <given-names>K</given-names></name><name><surname>Lath</surname> <given-names>D</given-names></name><name><surname>Bouxsein</surname> <given-names>ML</given-names></name><name><surname>Underwood</surname> <given-names>KW</given-names></name><name><surname>Ucran</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Pobre</surname> <given-names>E</given-names></name><name><surname>Grinberg</surname> <given-names>A</given-names></name><name><surname>Seehra</surname> <given-names>J</given-names></name><name><surname>Canalis</surname> <given-names>E</given-names></name><name><surname>Pearsall</surname> <given-names>RS</given-names></name><name><surname>Croucher</surname> <given-names>PI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength</article-title><source>PNAS</source><volume>109</volume><fpage>12207</fpage><lpage>12212</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204929109</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broege</surname> <given-names>A</given-names></name><name><surname>Pham</surname> <given-names>L</given-names></name><name><surname>Jensen</surname> <given-names>ED</given-names></name><name><surname>Emery</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>T-H</given-names></name><name><surname>Stemig</surname> <given-names>M</given-names></name><name><surname>Beppu</surname> <given-names>H</given-names></name><name><surname>Petryk</surname> <given-names>A</given-names></name><name><surname>O'Connor</surname> <given-names>M</given-names></name><name><surname>Mansky</surname> <given-names>K</given-names></name><name><surname>Gopalakrishnan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bone Morphogenetic Proteins Signal Via SMAD and Mitogen-activated Protein (MAP) Kinase Pathways at Distinct Times during Osteoclastogenesis</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>37230</fpage><lpage>37240</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.496950</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centis</surname> <given-names>F</given-names></name><name><surname>Tabellini</surname> <given-names>L</given-names></name><name><surname>Lucarelli</surname> <given-names>G</given-names></name><name><surname>Buffi</surname> <given-names>O</given-names></name><name><surname>Tonucci</surname> <given-names>P</given-names></name><name><surname>Persini</surname> <given-names>B</given-names></name><name><surname>Annibali</surname> <given-names>M</given-names></name><name><surname>Emiliani</surname> <given-names>R</given-names></name><name><surname>Iliescu</surname> <given-names>A</given-names></name><name><surname>Rapa</surname> <given-names>S</given-names></name><name><surname>Rossi</surname> <given-names>R</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Angelucci</surname> <given-names>E</given-names></name><name><surname>Schrier</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major</article-title><source>Blood</source><volume>96</volume><fpage>3624</fpage><lpage>3629</lpage><pub-id pub-id-type="doi">10.1182/blood.V96.10.3624</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname> <given-names>A</given-names></name><name><surname>Le Drévo</surname> <given-names>MA</given-names></name><name><surname>Moreau</surname> <given-names>MF</given-names></name><name><surname>Guillet</surname> <given-names>C</given-names></name><name><surname>Baslé</surname> <given-names>MF</given-names></name><name><surname>Chappard</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Isolation of osteoprogenitors from murine bone marrow by selection of CD11b negative cells</article-title><source>Cytotechnology</source><volume>58</volume><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1007/s10616-009-9184-1</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyment</surname> <given-names>NA</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Hong</surname> <given-names>S-H</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Ackert-Bicknell</surname> <given-names>C</given-names></name><name><surname>Shin</surname> <given-names>D-G</given-names></name><name><surname>Rowe</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High-Throughput, Multi-Image cryohistology of mineralized tissues</article-title><source>Journal of Visualized Experiments</source><volume>115</volume><elocation-id>54468</elocation-id><pub-id pub-id-type="doi">10.3791/54468</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname> <given-names>T</given-names></name><name><surname>Jung</surname> <given-names>G</given-names></name><name><surname>Naeim</surname> <given-names>A</given-names></name><name><surname>Ginzburg</surname> <given-names>Y</given-names></name><name><surname>Pakbaz</surname> <given-names>Z</given-names></name><name><surname>Walter</surname> <given-names>PB</given-names></name><name><surname>Kautz</surname> <given-names>L</given-names></name><name><surname>Nemeth</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunoassay for human serum erythroferrone</article-title><source>Blood</source><volume>130</volume><fpage>1243</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-04-777987</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooding</surname> <given-names>S</given-names></name><name><surname>Olechnowicz</surname> <given-names>SWZ</given-names></name><name><surname>Morris</surname> <given-names>EV</given-names></name><name><surname>Armitage</surname> <given-names>AE</given-names></name><name><surname>Arezes</surname> <given-names>J</given-names></name><name><surname>Frost</surname> <given-names>J</given-names></name><name><surname>Repapi</surname> <given-names>E</given-names></name><name><surname>Edwards</surname> <given-names>JR</given-names></name><name><surname>Ashley</surname> <given-names>N</given-names></name><name><surname>Waugh</surname> <given-names>C</given-names></name><name><surname>Gray</surname> <given-names>N</given-names></name><name><surname>Martinez-Hackert</surname> <given-names>E</given-names></name><name><surname>Lim</surname> <given-names>PJ</given-names></name><name><surname>Pasricha</surname> <given-names>S-R</given-names></name><name><surname>Knowles</surname> <given-names>H</given-names></name><name><surname>Mead</surname> <given-names>AJ</given-names></name><name><surname>Ramasamy</surname> <given-names>K</given-names></name><name><surname>Drakesmith</surname> <given-names>H</given-names></name><name><surname>Edwards</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4533</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12296-1</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guggenbuhl</surname> <given-names>P</given-names></name><name><surname>Bodic</surname> <given-names>F</given-names></name><name><surname>Hamel</surname> <given-names>L</given-names></name><name><surname>Baslé</surname> <given-names>MF</given-names></name><name><surname>Chappard</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Texture analysis of X-ray radiographs of iliac bone is correlated with bone micro-CT</article-title><source>Osteoporosis International</source><volume>17</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1007/s00198-005-0007-8</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevitch</surname> <given-names>O</given-names></name><name><surname>Slavin</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The hematological etiology of osteoporosis</article-title><source>Medical Hypotheses</source><volume>67</volume><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2006.03.051</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haidar</surname> <given-names>R</given-names></name><name><surname>Musallam</surname> <given-names>KM</given-names></name><name><surname>Taher</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bone disease and skeletal complications in patients with β thalassemia major</article-title><source>Bone</source><volume>48</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2010.10.173</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Bone morphogenetic proteins: multifunctional regulators of vertebrate development</article-title><source>Genes &amp; Development</source><volume>10</volume><fpage>1580</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1101/gad.10.13.1580</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imel</surname> <given-names>EA</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>McQueen</surname> <given-names>AK</given-names></name><name><surname>Acton</surname> <given-names>D</given-names></name><name><surname>Acton</surname> <given-names>A</given-names></name><name><surname>Padgett</surname> <given-names>LR</given-names></name><name><surname>Peacock</surname> <given-names>M</given-names></name><name><surname>Econs</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women</article-title><source>Bone</source><volume>86</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2016.03.005</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname> <given-names>ED</given-names></name><name><surname>Gopalakrishnan</surname> <given-names>R</given-names></name><name><surname>Westendorf</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Bone Morphogenic Protein 2 Activates Protein Kinase D to Regulate Histone Deacetylase 7 Localization and Repression of Runx2</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>2225</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1074/jbc.M800586200</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname> <given-names>N</given-names></name><name><surname>Ye</surname> <given-names>L</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Mochida</surname> <given-names>Y</given-names></name><name><surname>Yamauchi</surname> <given-names>M</given-names></name><name><surname>Kronenberg</surname> <given-names>HM</given-names></name><name><surname>Feng</surname> <given-names>JQ</given-names></name><name><surname>Mishina</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway</article-title><source>Development</source><volume>135</volume><fpage>3801</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.1242/dev.025825</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname> <given-names>N</given-names></name><name><surname>Shuxian</surname> <given-names>L</given-names></name><name><surname>Yamaguchi</surname> <given-names>R</given-names></name><name><surname>Phipps</surname> <given-names>M</given-names></name><name><surname>Aruwajoye</surname> <given-names>O</given-names></name><name><surname>Adapala</surname> <given-names>NS</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>HKW</given-names></name><name><surname>Feng</surname> <given-names>JQ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength</article-title><source>Bone</source><volume>91</volume><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2016.07.002</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautz</surname> <given-names>L</given-names></name><name><surname>Jung</surname> <given-names>G</given-names></name><name><surname>Valore</surname> <given-names>EV</given-names></name><name><surname>Rivella</surname> <given-names>S</given-names></name><name><surname>Nemeth</surname> <given-names>E</given-names></name><name><surname>Ganz</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of erythroferrone as an erythroid regulator of iron metabolism</article-title><source>Nature Genetics</source><volume>46</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/ng.2996</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautz</surname> <given-names>L</given-names></name><name><surname>Jung</surname> <given-names>G</given-names></name><name><surname>Du</surname> <given-names>X</given-names></name><name><surname>Gabayan</surname> <given-names>V</given-names></name><name><surname>Chapman</surname> <given-names>J</given-names></name><name><surname>Nasoff</surname> <given-names>M</given-names></name><name><surname>Nemeth</surname> <given-names>E</given-names></name><name><surname>Ganz</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia</article-title><source>Blood</source><volume>126</volume><fpage>2031</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-07-658419</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koide</surname> <given-names>M</given-names></name><name><surname>Kobayashi</surname> <given-names>Y</given-names></name><name><surname>Yamashita</surname> <given-names>T</given-names></name><name><surname>Uehara</surname> <given-names>S</given-names></name><name><surname>Nakamura</surname> <given-names>M</given-names></name><name><surname>Hiraoka</surname> <given-names>BY</given-names></name><name><surname>Ozaki</surname> <given-names>Y</given-names></name><name><surname>Iimura</surname> <given-names>T</given-names></name><name><surname>Yasuda</surname> <given-names>H</given-names></name><name><surname>Takahashi</surname> <given-names>N</given-names></name><name><surname>Udagawa</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts</article-title><source>Journal of Bone and Mineral Research</source><volume>32</volume><fpage>2074</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3175</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowski</surname> <given-names>JL</given-names></name><name><surname>Kim</surname> <given-names>H-Y</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Quinn</surname> <given-names>CT</given-names></name><name><surname>Mueller</surname> <given-names>BU</given-names></name><name><surname>Odame</surname> <given-names>I</given-names></name><name><surname>Giardina</surname> <given-names>PJ</given-names></name><name><surname>Vichinsky</surname> <given-names>EP</given-names></name><name><surname>Boudreaux</surname> <given-names>JM</given-names></name><name><surname>Cohen</surname> <given-names>AR</given-names></name><name><surname>Porter</surname> <given-names>JB</given-names></name><name><surname>Coates</surname> <given-names>T</given-names></name><name><surname>Olivieri</surname> <given-names>NF</given-names></name><name><surname>Neufeld</surname> <given-names>EJ</given-names></name><collab>for the Thalassemia Clinical Research Network</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort</article-title><source>Blood</source><volume>119</volume><fpage>2746</fpage><lpage>2753</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-04-344507</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacativa</surname> <given-names>PG</given-names></name><name><surname>Farias</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Osteoporosis and inflammation</article-title><source>Arquivos Brasileiros De Endocrinologia &amp; Metabologia</source><volume>54</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1590/S0004-27302010000200007</pub-id><pub-id pub-id-type="pmid">20485900</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Choesang</surname> <given-names>T</given-names></name><name><surname>Bao</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Feola</surname> <given-names>M</given-names></name><name><surname>Garcia-Santos</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>S</given-names></name><name><surname>Follenzi</surname> <given-names>A</given-names></name><name><surname>Pham</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Ponka</surname> <given-names>P</given-names></name><name><surname>An</surname> <given-names>X</given-names></name><name><surname>Mohandas</surname> <given-names>N</given-names></name><name><surname>Fleming</surname> <given-names>RE</given-names></name><name><surname>Rivella</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Ginzburg</surname> <given-names>YZ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice</article-title><source>Blood</source><volume>129</volume><fpage>1514</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-742387</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maridas</surname> <given-names>DE</given-names></name><name><surname>Rendina-Ruedy</surname> <given-names>E</given-names></name><name><surname>Le</surname> <given-names>PT</given-names></name><name><surname>Rosen</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice</article-title><source>Journal of Visualized Experiments</source><volume>131</volume><elocation-id>e56750</elocation-id><pub-id pub-id-type="doi">10.3791/56750</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlin</surname> <given-names>S</given-names></name><name><surname>Cannizzo</surname> <given-names>ES</given-names></name><name><surname>Borroni</surname> <given-names>E</given-names></name><name><surname>Bruscaggin</surname> <given-names>V</given-names></name><name><surname>Schinco</surname> <given-names>P</given-names></name><name><surname>Tulalamba</surname> <given-names>W</given-names></name><name><surname>Chuah</surname> <given-names>MK</given-names></name><name><surname>Arruda</surname> <given-names>VR</given-names></name><name><surname>VandenDriessche</surname> <given-names>T</given-names></name><name><surname>Prat</surname> <given-names>M</given-names></name><name><surname>Valente</surname> <given-names>G</given-names></name><name><surname>Follenzi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice</article-title><source>Molecular Therapy</source><volume>25</volume><fpage>1815</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.04.029</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname> <given-names>E</given-names></name><name><surname>Roetto</surname> <given-names>A</given-names></name><name><surname>Garozzo</surname> <given-names>G</given-names></name><name><surname>Ganz</surname> <given-names>T</given-names></name><name><surname>Camaschella</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Hepcidin is decreased in TFR2 hemochromatosis</article-title><source>Blood</source><volume>105</volume><fpage>1803</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-08-3042</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Campo</surname> <given-names>FM</given-names></name><name><surname>Santurtún</surname> <given-names>A</given-names></name><name><surname>García-Ibarbia</surname> <given-names>C</given-names></name><name><surname>Pascual</surname> <given-names>MA</given-names></name><name><surname>Valero</surname> <given-names>C</given-names></name><name><surname>Garcés</surname> <given-names>C</given-names></name><name><surname>Sañudo</surname> <given-names>C</given-names></name><name><surname>Zarrabeitia</surname> <given-names>MT</given-names></name><name><surname>Riancho</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone</article-title><source>Calcified Tissue International</source><volume>99</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s00223-016-0144-4</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pootrakul</surname> <given-names>P</given-names></name><name><surname>Kitcharoen</surname> <given-names>K</given-names></name><name><surname>Yansukon</surname> <given-names>P</given-names></name><name><surname>Wasi</surname> <given-names>P</given-names></name><name><surname>Fucharoen</surname> <given-names>S</given-names></name><name><surname>Charoenlarp</surname> <given-names>P</given-names></name><name><surname>Brittenham</surname> <given-names>G</given-names></name><name><surname>Pippard</surname> <given-names>MJ</given-names></name><name><surname>Finch</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>The effect of erythroid hyperplasia on iron balance</article-title><source>Blood</source><volume>71</volume><fpage>1124</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1182/blood.V71.4.1124.1124</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauner</surname> <given-names>M</given-names></name><name><surname>Baschant</surname> <given-names>U</given-names></name><name><surname>Roetto</surname> <given-names>A</given-names></name><name><surname>Pellegrino</surname> <given-names>RM</given-names></name><name><surname>Rother</surname> <given-names>S</given-names></name><name><surname>Salbach-Hirsch</surname> <given-names>J</given-names></name><name><surname>Weidner</surname> <given-names>H</given-names></name><name><surname>Hintze</surname> <given-names>V</given-names></name><name><surname>Campbell</surname> <given-names>G</given-names></name><name><surname>Petzold</surname> <given-names>A</given-names></name><name><surname>Lemaitre</surname> <given-names>R</given-names></name><name><surname>Henry</surname> <given-names>I</given-names></name><name><surname>Bellido</surname> <given-names>T</given-names></name><name><surname>Theurl</surname> <given-names>I</given-names></name><name><surname>Altamura</surname> <given-names>S</given-names></name><name><surname>Colucci</surname> <given-names>S</given-names></name><name><surname>Muckenthaler</surname> <given-names>MU</given-names></name><name><surname>Schett</surname> <given-names>G</given-names></name><name><surname>Komla-Ebri</surname> <given-names>DSK</given-names></name><name><surname>Bassett</surname> <given-names>JHD</given-names></name><name><surname>Williams</surname> <given-names>GR</given-names></name><name><surname>Platzbecker</surname> <given-names>U</given-names></name><name><surname>Hofbauer</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s42255-018-0005-8</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rund</surname> <given-names>D</given-names></name><name><surname>Rachmilewitz</surname> <given-names>E</given-names></name><name><surname>Beta-thalassemia</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>β-Thalassemia</article-title><source>New England Journal of Medicine</source><volume>353</volume><fpage>1135</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1056/NEJMra050436</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname> <given-names>VS</given-names></name><name><surname>Gamer</surname> <given-names>LW</given-names></name><name><surname>Rosen</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>BMP signalling in skeletal development, disease and repair</article-title><source>Nature Reviews Endocrinology</source><volume>12</volume><fpage>203</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2016.12</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname> <given-names>CM</given-names></name><name><surname>Mesquita</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Bone Marrow Composition and Bone Microarchitecture and Turnover in Blacks and Whites</article-title><source>Journal of Bone and Mineral Research</source><volume>13</volume><fpage>1300</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1359/jbmr.1998.13.8.1300</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname> <given-names>AV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Marrow fat and bone: review of clinical findings</article-title><source>Frontiers in Endocrinology</source><volume>6</volume><elocation-id>40</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2015.00040</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Uyeda</surname> <given-names>M</given-names></name><name><surname>Tanjaya</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>JK</given-names></name><name><surname>Pan</surname> <given-names>HC</given-names></name><name><surname>Reese</surname> <given-names>P</given-names></name><name><surname>Stodieck</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>A</given-names></name><name><surname>Ting</surname> <given-names>K</given-names></name><name><surname>Kwak</surname> <given-names>JH</given-names></name><name><surname>Soo</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Guidelines for Dual Energy X-Ray Absorptiometry Analysis of Trabecular Bone-Rich Regions in Mice: Improved Precision, Accuracy, and Sensitivity for Assessing Longitudinal Bone Changes</article-title><source>Tissue Engineering Part C: Methods</source><volume>22</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1089/ten.tec.2015.0383</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singbrant</surname> <given-names>S</given-names></name><name><surname>Russell</surname> <given-names>MR</given-names></name><name><surname>Jovic</surname> <given-names>T</given-names></name><name><surname>Liddicoat</surname> <given-names>B</given-names></name><name><surname>Izon</surname> <given-names>DJ</given-names></name><name><surname>Purton</surname> <given-names>LE</given-names></name><name><surname>Sims</surname> <given-names>NA</given-names></name><name><surname>Martin</surname> <given-names>TJ</given-names></name><name><surname>Sankaran</surname> <given-names>VG</given-names></name><name><surname>Walkley</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment</article-title><source>Blood</source><volume>117</volume><fpage>5631</fpage><lpage>5642</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-11-320564</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Thalassemia Clinical Research Network</collab><name><surname>Tubman</surname> <given-names>VN</given-names></name><name><surname>Fung</surname> <given-names>EB</given-names></name><name><surname>Vogiatzi</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Rogers</surname> <given-names>ZR</given-names></name><name><surname>Neufeld</surname> <given-names>EJ</given-names></name><name><surname>Kwiatkowski</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort</article-title><source>Journal of Pediatric Hematology/Oncology</source><volume>37</volume><fpage>e162</fpage><lpage>e169</lpage><pub-id pub-id-type="doi">10.1097/MPH.0000000000000307</pub-id><pub-id pub-id-type="pmid">26201037</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van 't Hof</surname> <given-names>RJ</given-names></name><name><surname>Rose</surname> <given-names>L</given-names></name><name><surname>Bassonga</surname> <given-names>E</given-names></name><name><surname>Daroszewska</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Open source software for semi-automated histomorphometry of bone resorption and formation parameters</article-title><source>Bone</source><volume>99</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2017.03.051</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogiatzi</surname> <given-names>MG</given-names></name><name><surname>Macklin</surname> <given-names>EA</given-names></name><name><surname>Fung</surname> <given-names>EB</given-names></name><name><surname>Vichinsky</surname> <given-names>E</given-names></name><name><surname>Olivieri</surname> <given-names>N</given-names></name><name><surname>Kwiatkowski</surname> <given-names>J</given-names></name><name><surname>Cohen</surname> <given-names>A</given-names></name><name><surname>Neufeld</surname> <given-names>E</given-names></name><name><surname>Giardina</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Prevalence of fractures among the Thalassemia syndromes in North America</article-title><source>Bone</source><volume>38</volume><fpage>571</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2005.10.001</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogiatzi</surname> <given-names>MG</given-names></name><name><surname>Tsay</surname> <given-names>J</given-names></name><name><surname>Verdelis</surname> <given-names>K</given-names></name><name><surname>Rivella</surname> <given-names>S</given-names></name><name><surname>Grady</surname> <given-names>RW</given-names></name><name><surname>Doty</surname> <given-names>S</given-names></name><name><surname>Giardina</surname> <given-names>PJ</given-names></name><name><surname>Boskey</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Changes in Bone Microarchitecture and Biomechanical Properties in the th3 Thalassemia Mouse are Associated with Decreased Bone Turnover and Occur During the Period of Bone Accrual</article-title><source>Calcified Tissue International</source><volume>86</volume><fpage>484</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s00223-010-9365-0</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname> <given-names>DF</given-names></name><name><surname>Summerville</surname> <given-names>L</given-names></name><name><surname>Crampton</surname> <given-names>EM</given-names></name><name><surname>Frazer</surname> <given-names>DM</given-names></name><name><surname>Anderson</surname> <given-names>GJ</given-names></name><name><surname>Subramaniam</surname> <given-names>VN</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload</article-title><source>Hepatology</source><volume>50</volume><fpage>1992</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1002/hep.23198</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C-Y</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Traeger</surname> <given-names>L</given-names></name><name><surname>Dogan</surname> <given-names>DY</given-names></name><name><surname>Xiao</surname> <given-names>X</given-names></name><name><surname>Steinbicker</surname> <given-names>AU</given-names></name><name><surname>Babitt</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3</article-title><source>Blood</source><volume>135</volume><fpage>453</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002620</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatherall</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>4 Pathophysiology of thalassaemia</article-title><source>Baillière's Clinical Haematology</source><volume>11</volume><fpage>127</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S0950-3536(98)80072-3</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatherall</surname> <given-names>DJ</given-names></name><name><surname>Williams</surname> <given-names>TN</given-names></name><name><surname>Allen</surname> <given-names>SJ</given-names></name><name><surname>O’Donnell</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Population Genetics and Dynamics of the Thalassemias</article-title><source>Hematology/Oncology Clinics of North America</source><volume>24</volume><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2010.08.010</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Iron loading: a risk factor for osteoporosis</article-title><source>BioMetals</source><volume>19</volume><fpage>633</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1007/s10534-006-9000-8</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>B</given-names></name><name><surname>Kirby</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>J</given-names></name><name><surname>Detloff</surname> <given-names>PJ</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Smithies</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A mouse model for beta 0-thalassemia</article-title><source>PNAS</source><volume>92</volume><fpage>11608</fpage><lpage>11612</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.25.11608</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>So</surname> <given-names>S</given-names></name><name><surname>de Crombrugghe</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sclerostin is a direct target of osteoblast-specific transcription factor osterix</article-title><source>Biochemical and Biophysical Research Communications</source><volume>400</volume><fpage>684</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.08.128</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Skeletal remodeling in health and disease</article-title><source>Nature Medicine</source><volume>13</volume><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/nm1593</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68217.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Mohan</surname><given-names>Subburaman</given-names></name><role>Reviewing Editor</role><aff><institution>Loma Linda University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Mohan</surname><given-names>Subburaman</given-names> </name><role>Reviewer</role><aff><institution>Loma Linda University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The demonstration of an osteoprotective effect of erythroblast erythroferrone throughmodulating both osteoblastic and osteoclastic activity is novel and applicable not only to b-thalassemia but potentially to other conditions as well.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The Hepcidin Regulator Erythroferrone is a New Member of the Erythropoiesis-Iron-Bone Circuitry&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Subburaman Mohan as the Reviewing Editor and Reviewer #2, and the evaluation has been overseen by Carlos Isales as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. It appears that all of the experimental work was done in male mice. No rationale was provided for why only male mice were used. In this regard, a recent study showed that erythroid promoting effects of androgens are mediated via increasing erythropoietin expression and its downstream target, EFRE (McManus et al., Eur J Hematology, April 2020, PMID: 32311143). The authors should explain the rationale for choosing male mice in the context of published data and whether the findings are expected to be relevant in female mice.</p><p>2. Figure 1A shows that while L4-6 BMD was decreased, BV/TV was increased. It is unclear if the BV/TV was measured by histology. The authors should address the discrepancy between the decreased BMD versus increased BV/TV in the 6-week old mice.</p><p>3. While both BMP2 and BMP6 are known to interact with ERFE, the authors have focused on BMP2. Did the authors measure BMP6 levels in the conditioned medium of EFRE knockout osteoblasts? Do the authors believe that BMP2 is the major mediator of ERFE effects in osteoblasts to regulate osteoclast functions?</p><p>4. Mice lacking ERFE show increased bone formation rates at younger age despite increased expression of Sclerostin. It would help the authors more extensively discuss those findings, and modify the schematic figure accordingly.</p><p>5. n 5-month-old Erfe-/-mice, the result showed enhanced osteoblast differentiation and mineralization with enhanced expression of Runx2and Sp7, and Sost and Tnfsf11 in Figure 4A and B, however, in Figure 1D, there is no differences in MS, MAR, and BFR.</p><p>6. In Figure 3C, it is not clear why Smad1 and ERK 1/2 level were changed in ERFE deleted cells and wild type cells when treated with or without BMP2, while pSmad1/5/8 did not respond to BMP2 stimulation in the wild type group, which are inconsistent to published results in osteoblasts.</p><p>7. To probe the mechanism of action of ERFE on osteoblastic bone formation and osteoclastic bone resorption, bone marrow cells were induced with osteoblastic differentiating media for different times. It is likely that the cultures contain other cell types besides osteoblast line cells at early time points.</p><p>8. The authors should discuss potential explanation for the differences in skeletal phenotype between ERFE knockout and control mice at 6-week-old vs 5-month-old animals.</p><p>In this study, Castro-Mollo and colleagues report the novel and groundbreaking finding that erytroferrone (ERFE) is produced and secreted by osteoblasts, i.e. the cells forming bone, at high levels and in an EPO-independent fashion. More importantly, ERFE regulates bone mass as its loss leads to a low bone mass phenotype.. The bone loss is secondary to an increase of bone resorption due to an augmented production of RANKL and sclerostin by osteoblasts via higher availability of BMPs.</p><p>The paper provides novel and exciting information, which is likely to open a new field of investigation. The study, which is both highly mechanistic and translationally relevant, spurs a wealth of interesting questions. The findings are solid and convincing from both a biological and a translational standpoint. The authors' conclusions are supported by the data as shown.</p><p>The study is highly significant for the treatment of low bone mass in patients with β-thalassemia, which is a yet unexplored field of research. Β-Thalassemia is a devastating genetic disease in which severe anemia is associated with high levels of ERFE. While the data in general support the overall conclusion regarding a role for EFRE in the regulation of bone metabolism, the authors should address the recommended revisions of the review panel mentioned above to improve the clarity of the manuscript.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68217.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. It appears that all of the experimental work was done in male mice. No rationale was provided for why only male mice were used. In this regard, a recent study showed that erythroid promoting effects of androgens are mediated via increasing erythropoietin expression and its downstream target, EFRE (McManus et al., Eur J Hematology, April 2020, PMID: 32311143). The authors should explain the rationale for choosing male mice in the context of published data and whether the findings are expected to be relevant in female mice.</p></disp-quote><p>We anticipated that the gender effect on erythropoiesis and bone metabolism would require separate evaluation of the genders and selected male mice for efficient use of our mouse colony. We anticipate that the effects of ERFE loss would also yield significant differences in female mice. Ultimately, a separate evaluation in female mice is also warranted. McManus et al. note that androgens promote erythropoiesis by a DNA binding-dependent mechanism to stimulate Epo expression in non-hematopoietic cells, leading to ERFE production by erythroblasts. Importantly, McManus et al. demonstrate no differences in serum Epo or bone marrow <italic>Erfe</italic> expression between male and female wild type mice (vehicle treated). As a consequence, we anticipate that differences between female wild type and <italic>Erfe</italic><sup>-/-</sup> as well as between <italic>Hbb<sup>th3/+</sup></italic> and <italic>Hbb<sup>th3/+</sup></italic>;<italic>Erfe</italic><sup>-/-</sup> mice would reflect differences similar to those presented in male mice in the current manuscript. Finally, given the greater bone mineral density in male relative to female C57BL/6 mice [Glatt J Bone Miner Res 2007], ERFE loss may have even more pronounced effects in female relative to male mice.</p><p>We have added the following statement to the Discussion section (page 15):</p><p>“The results presented reflect evidence derived from analysis of male mice. We anticipate that similar differences would be expected in female mice.”</p><disp-quote content-type="editor-comment"><p>2. Figure 1A shows that while L4-6 BMD was decreased, BV/TV was increased. It is unclear if the BV/TV was measured by histology. The authors should address the discrepancy between the decreased BMD versus increased BV/TV in the 6-week old mice.</p></disp-quote><p>We appreciate this request for clarification. BV/TV was measured using Von Kossa stained histomorphometry slides; this has been noted in the Skeletal Phenotyping part of the Methods section. Furthermore, we hypothesize that ERFE loss directly enhances osteoblastogenesis, leading to increased BV/TV, and directly enhances osteoclastogenesis, ultimately leading to decreased bone mineral density (see also response to point #4). We hypothesize that the increase in BV/TV is transient and disappears as the mice age, when the cumulative effect on bone resorption is evident. We have added a new panel to Figure 6, namely Figure 6C, to specifically provide a visual representation of this point.</p><disp-quote content-type="editor-comment"><p>3. While both BMP2 and BMP6 are known to interact with ERFE, the authors have focused on BMP2. Did the authors measure BMP6 levels in the conditioned medium of EFRE knockout osteoblasts? Do the authors believe that BMP2 is the major mediator of ERFE effects in osteoblasts to regulate osteoclast functions?</p></disp-quote><p>We appreciate this query. Taken together, our findings that serum BMP2 concentration is elevated in <italic>Erfe<sup>-/-</sup></italic> mice, consistent with increased BMP2 concentration in cultured <italic>Erfe<sup>-/-</sup></italic> osteoblast supernatants, and the diminished effect of added BMP2 on signaling in <italic>Erfe<sup>-/-</sup></italic> relative to WT osteoblasts, provide definitive in vivo and in vitro evidence of ERFE-dependent effects on BMP2.</p><p>As the reviewer states, while ERFE has been found to sequester both BMP6 and BMP2 [Arezes Blood 2018; Wang Blood 2020], we focused on BMP2 given its role in bone remodeling [Salazar Nat Rev Endocrinol 2016]. No reagents are available for easily measuring BMP6 in osteoblast conditioned media. To test whether an ERFE effect on bone is BMP2 specific, we evaluated the effect of BMP6 in osteoblasts in vitro, demonstrating similar responses in signaling to those observed with BMP2 in wild type and <italic>Erfe</italic><sup>-/-</sup> osteoblasts in vitro (Figure 3C and 3D). We have added this data to new Figure 3—figure supplement 3 in the revised manuscript.</p><p>Finally, in response to the reviewer’s question, we believe that increased BMPs lead to activation of BMP signaling in <italic>Erfe</italic><sup>-/-</sup> osteoblasts to stimulate osteoblast differentiation. This is based on the observation that BMPs are increased in the supernatant of <italic>Erfe</italic><sup>-/-</sup> osteoblasts leading to greater activation of BMP signaling and a blunted effect in response to exogenously added BMPs. However, specifically which BMP is the primary physiological actor in this pathway is incompletely understood. To address this, we have edited this part of the Results section (page 12) and the Discussion section to reflect an ERFE effect on bone via sequestration of BMPs more generally.</p><disp-quote content-type="editor-comment"><p>4. Mice lacking ERFE show increased bone formation rates at younger age despite increased expression of Sclerostin. It would help the authors more extensively discuss those findings, and modify the schematic figure accordingly.</p></disp-quote><p>We appreciate this request for clarification. The reviewer correctly notes that while the in vivo data demonstrates increased bone formation rate in <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice (Figure 1C), in vitro data demonstrates increased <italic>Sost</italic> expression in cultured osteoblasts from <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice (Figure 4B) which would be expected to decrease—rather than increase—the bone formation rate. It has been shown that sclerostin inhibits Wnt signaling, providing negative feedback and preventing further osteoblast differentiation [Tanaka J Bone Miner Metab 2021]. Sclerostin also optimizes the relative proportion of RANKL and OPG to induce bone resorption [Takayanagi Nat Rev Immun 2007]. Our results confirm decreased <italic>Opg</italic> expression (Figure 4B) and increased RANKL concentration (Figure 4C) in <italic>Erfe</italic><sup>-/-</sup> relative to wild type osteoblasts in vitro. Taken together, these findings strongly suggest that while ERFE loss leads to increased bone mineralization in vitro, in vivo effects of enhanced osteoblast function and gene expression result in enhanced osteoclastogenesis in <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice (Figure 1F), culminating in decreased bone mineral density.</p><p>Furthermore, we have added additional statistical calibration to Figure 1 to provide evidence that the phenotype in younger mice is similar to that in older mice and have edited the Results section accordingly.</p><p>Finally, in response to this query, we have expanded Figure 6 to include Figure 6C to visually address this point and added the following paragraph to the Discussion section (page 15):</p><p>“Bone is a highly dynamic and purposefully organized tissue which undergoes constant remodeling in response to changing metabolic and mechanical needs. […] Our findings demonstrate that while ERFE loss leads to increased bone mineralization in vitro and bone formation increases as expected with age, the composite effect in vivo results in greater enhancement of osteoclastogenesis relative to osteoblastogenesis in <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice, consequently decreasing bone mineral density (Figure 6C).”</p><disp-quote content-type="editor-comment"><p>5. n 5-month-old Erfe-/-mice, the result showed enhanced osteoblast differentiation and mineralization with enhanced expression of Runx2and Sp7, and Sost and Tnfsf11 in Figure 4A and B, however, in Figure 1D, there is no differences in MS, MAR, and BFR.</p></disp-quote><p>We appreciate the differences between in vivo and in vitro results and interpret the query as a request for comment on this point. It is our interpretation that while in vitro results enable cell-autonomous effect of ERFE loss in osteoblasts, the effects in vivo are influenced also by the osteoblast-dependent effects on osteoclasts (see also response to #2 and #4). As a consequence, increased bone mineralization in vitro in <italic>Erfe</italic><sup>-/-</sup> relative to wild type osteoblasts results in increased <italic>Tnfsf11</italic> and decreased <italic>Opg</italic> mRNA expression as well as increased RANKL concentration in the supernatant. These findings would be expected to cause increased osteoclast surface and osteoclast number in vivo as we demonstrate in 5-month-old <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice to explain a lack of difference in MS, MAR, and BFR between <italic>Erfe</italic><sup>-/-</sup> and wild type mice.</p><disp-quote content-type="editor-comment"><p>6. In Figure 3C, it is not clear why Smad1 and ERK 1/2 level were changed in ERFE deleted cells and wild type cells when treated with or without BMP2, while pSmad1/5/8 did not respond to BMP2 stimulation in the wild type group, which are inconsistent to published results in osteoblasts.</p></disp-quote><p>We regret not making this more clear and have re-organized Figure 3C and 3D for further clarity. pSmad1/5/8 and pERK1/2 both increase in <italic>Erfe</italic><sup>-/-</sup> relative to wild type osteoblasts. Furthermore, pSmad1/5/8 and pERK1/2 are both increased in response to BMP2 in wild type but not <italic>Erfe</italic><sup>-/-</sup> osteoblasts. No differences are observed in pp38/MAPK signaling.</p><disp-quote content-type="editor-comment"><p>7. To probe the mechanism of action of ERFE on osteoblastic bone formation and osteoclastic bone resorption, bone marrow cells were induced with osteoblastic differentiating media for different times. It is likely that the cultures contain other cell types besides osteoblast line cells at early time points.</p></disp-quote><p>We appreciate this potential confounder. However, a hierarchical differentiation tree available from BloodSpot demonstrates the erythroid specificity (MEP) of ERFE (gene name Fam132b) expression in healthy individuals:</p><fig id="sa1fig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68217-resp-fig1-v2.tif"/></fig><p>Furthermore, our data demonstrates that alkaline phosphatase, a well-established marker of osteoblastic lineage, is increased as early as day 3 in culture (new Figure 2—figure supplement 2), confirming the presence of osteoblasts. Taken together, the lack of Epo in these culture conditions coupled with the lack of adhesiveness of erythroid lineage cells and rapid increase in alkaline phosphatase together strongly support the osteoblast-specific production of ERFE in this culture system. This information has been added to the Methods and Results sections.</p><disp-quote content-type="editor-comment"><p>8. The authors should discuss potential explanation for the differences in skeletal phenotype between ERFE knockout and control mice at 6-week-old vs 5-month-old animals.</p></disp-quote><p>We appreciate this request for clarification. We intentionally compared growing (6-week-old) and mature (5-month-old) mice to assess the potentially distinct or cumulative effect of ERFE loss on bone growth and / or remodeling, respectively. Our results demonstrate that ERFE loss leads to impaired BMD in both cohorts of mice. However, while MS/BS, MAR, BFR and BV/TV are increased in 6-week-old <italic>Erfe</italic><sup>-/-</sup> relative to wild type mice, no differences are evident between 5-month-old <italic>Erfe</italic><sup>-/-</sup> and wild type mice. These findings strongly suggest that over time, while both bone formation and resorption increase relative to younger mice, the balance between them favors bone resorption (new Figure 6C). This interpretation is further corroborated by a more profound increase in osteoclast surface and osteoclast number in 5-month-old <italic>Erfe</italic><sup>-/-</sup> relative to wild type than in 6-week-old mice.</p><p>We have added the following statement to the Discussion section (page 15) to address this point:</p><p>”We intentionally compared growing (6-week-old) and mature (5-month-old) mice to assess the potentially distinct or cumulative effect of ERFE loss on bone growth and / or remodeling, respectively. […] We are enthusiastic about the merits of this work and confident that it will advance the exploration and potential application of ERFE-related therapeutics in patients with disordered erythropoiesis and iron metabolism.</p></body></sub-article></article>